Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 07/02/20 at 12:44pm

The Wuhan coronavirus continues to dominate the news, with China admitting its handling of the crisis had shortcomings while Gilead has been testing its experimental Ebola drug on patients with the coronavirus. A baby born in February has also been diagnosed with the disease but doctors are still unclear if its infected mother transferred it during or after preganancy.

In other news, the FDA has approved its first treatment for peanut allergy in patients between ages four and 17, while Sanofi has been charged with failure to adequately warn patients about their anti-epilepsy drug which has been linked to birth defects.

10. NICE plans to use broader range of data in guidance

The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics in its guidance. This will include real-world evidence and electronic health records.

9. Bayer's Eylea shows strong vision benefits across two regimens in post-marketing study

Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment of wet age-related macular degeneration (AMD) via two different Treat and Extend (T&E) dosing regimens.

8. Europe's CHMP recommends Pfizer's biosimilar of Roche's MabThera

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has revealed that it has awarded a positive opinion for Pfizer’s Ruxience, a biosimilar version of Roche’s MabThera (rituximab).

7. Gilead’s experimental Ebola drug being tested in patients infected with coronavirus

China and the US are testing Gilead’s remdesivir in patients with the coronavirus, in the hopes of developing an effective treatment for a disease that does not yet have a vaccine.

6. Healthy cells in lungs can repair the damage from smoking

Human lungs have the ‘magical’ ability to repair the cancerous mutations caused by smoking cigarettes, but only if people quit smoking.

5. Sanofi charged in birth defects case in France

Sanofi has been charged with failure to adequately warn patients about their anti-epilepsy drug which has been linked to birth defects.

4. China admits its coronavirus response had “shortcomings”

In a rare move, China’s leadership has admitted “shortcomings” in the way it has handled the outbreak of the deadly coronavirus.

3. FDA approves first treatment for peanut allergy

The FDA has approved its first treatment for peanut allergy in patients between ages four and 17.

2. BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer

Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of advanced non-small cell lung cancer (NSCLC).

1. Newborn baby diagnosed with coronavirus

A baby born this month in Wuhan China has been diagnosed with the coronavirus.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches